Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.
Ciro
C
Romano
Ausilia
A
Sellitto
Umberto
U
De Fanis
Gaetano
G
Esposito
Paola
P
Arbo
Riccardo
R
Giunta
Giacomo
G
Lucivero
D000328:Adult; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D015549:Basophil Degranulation Test; D002908:Chronic Disease; D054796:Drug Dosage Calculations; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012074:Remission Induction; D014581:Urticaria / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E